Navigation Links
EntreMed to Present at BIO CEO and Investor Conference
Date:2/5/2008

ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BIO CEO and Investor Conference, to be held at the Waldorf-Astoria Hotel, February 11-13, 2008. Mr. Burns' presentation is scheduled for Tuesday, February 12, 2008 at 2:45 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel anticancer drug, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of ca
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
2. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
3. EntreMed Appoints Senior Vice President of Research and Development
4. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
7. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
8. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
10. inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference
11. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... A novel robotic system that can operate inside ... tested as part of a biomedical research partnership program ... aim of determining if the robot, in conjunction with ... more accurate, less costly, and less discomforting for the ... deliver prostate cancer therapies with greater precision. , Developed ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... On Tuesday, Secretary of Energy Ernest ... for National Lab Day on the Hill. The event ... laboratory system. Durbin and Risch also formally launched the ... of the reach of the national labs as leaders ... some of our nation's most pressing challenges. , "The ...
(Date:9/18/2014)... , Sept. 18, 2014 ... of the "Global N-acetylcysteine Industry Report 2014" ... The Global N-acetylcysteine Industry Report 2014 is a ... of the global N-acetylcysteine industry. The ... including definitions, classifications, applications and industry chain structure. ...
Breaking Biology Technology:Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2
... Therapeutics Inc., a,privately-held biotechnology company developing first-in-class ... it has closed the final,tranche of its ... Alta,Partners co-led the $16.7 million tranche, which ... Arch Partners, and Altitude Life Science,Ventures. ...
... is the bane of any machine. When moving parts ... them, the machine doesn,t operate as efficiently, and the parts ... But if you could manufacture parts that had tough, "slippery" ... the parts would last longer. Researchers at the U.S. ...
... HUBEI PROVINCE, China, Nov. 18 ,Benda Pharmaceutical, Inc. (OTC ... a commercialized gene,therapy medicine for the treatment of cancer, ... for the three and,nine month periods ended September 30, ... with the SEC today. , ...
Cached Biology Technology:Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing 2Nanocoatings boost industrial energy efficiency 2Nanocoatings boost industrial energy efficiency 3Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 2Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 3Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 4Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 5Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 6Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 7Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 8Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 9
(Date:9/18/2014)... lives nestling in the protective tentacles of host anemones, ... travel hundreds of kilometres across the open ocean. Although ... been predicted, this is the first time that the ... been observed. , Dr Steve Simpson, Senior Lecturer in ... Exeter, and colleagues from the Australian Research Council Centre ...
(Date:9/17/2014)... the creation of the Santa Ana Wildfire Threat Index ... potential of the powerful, hot, dry Santa Ana wind, ... index was introduced Sept. 17 by the U.S. Forest ... and Electric. , The index includes four classification levels ... to help fire agencies and other emergency responders, the ...
(Date:9/17/2014)... UT Arlington engineering professor and his doctoral student have ... can accumulate water collected from fog and dew., The ... world or deserts around the globe., Cheng Luo, professor ... Heng, PhD candidate in the same College of Engineering ... 25 edition of ACS, (American Chemical Society) ...
Breaking Biology News(10 mins):Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Shorebird's beak inspires UT Arlington research on water collection 2
... of Maryland School of Medicine has received a $7.9 million ... Resonance (NMR) magnet that will help researchers unravel the mysteries ... and other diseases. The grant is among the largest of ... Resources (NCRR), which is part of the National Institutes of ...
... of Texas at Dallas researcher and a university-affiliated biomedical ... a long-term cure for tinnitus. Described as a ... 40 percent of recently returned military veterans and about ... The U.S. Veterans Administration spends about $1 billion a ...
... haze hovering over Houston as a result of chemical pollution ... bit thinner, according to a new study. But ... around the world -- come with a catch, says a ... Environmental Sciences, or CIRES, a joint institute of the University ...
Cached Biology News:University of Maryland School of Medicine receives $7.9 million grant for 'super' research magnet 2Tinnitus study looks for cure to 'ringing in the ears' 2Tinnitus study looks for cure to 'ringing in the ears' 3Texas petrochemical emissions down, but still underestimated, says study 2
...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
... better net results - with a modular ... data management! The ChemStation Plus NDS family ... data acquisition and data management, giving you ... meets your labs needs now and that ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
Biology Products: